Gilead Sciences Inc. will pay $67 million for the remaining rights to a cancer immunotherapy drug from partner Jounce Therapeutics Inc., a move to strengthen the Foster City-based drug maker's pipeline of potential cancer drugs.
GS-1811 is designed to selectively deplete immune system-suppressing T regulatory cells that infiltrate the area in and around tumors, giving the body's immune system a better chance at fighting off the cancer. "GS-1811, with its potential new pathway of activating the immune system, gives us the opportunity to potentially change the standard of care with a treatment works from inside cancerous cells to shrink solid tumors," said Dr.Richard Murray
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut: